Obesity, ASCVD and PCSK9 Inhibition: What FOURIER Really Shows
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Obesity, ASCVD and PCSK9 Inhibition: What FOURIER Really Shows
Obesity = higher cardiovascular risk. In the placebo arm, every +5 BMI units above 30 kg/m² increased MACE risk by 11%.
Benefit of evolocumab grows as BMI increases.
•BMI <30: 11% RRR, ARR 1.4%
•BMI 30–34.9: 14% RRR, ARR 1.8%
•BMI ≥35: 29% RRR, ARR 5.7%, NNT = 17 at 3 years
LDL-C lowering remains equally powerful across all BMI categories (≈–56% to –61%). Obesity didn’t blunt the lipid response.
Inflammation amplifies risk. Highest MACE rates occurred in patients with both obesity and elevated hsCRP (>3 mg/L) – and this group also derived the largest benefit from evolocumab.
Key insight: Obesity appears to create an “atherogenic + inflammatory” residual-risk phenotype that is highly modifiable with intensive LDL-C lowering.
Clinical message: For ASCVD patients with obesity – particularly those with class 2–3 obesity or high hsCRP – PCSK9 inhibition is not optional; it’s essential.
Open access.”
Title: Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER
Authors: Yu Mi Kang, Robert P. Giugliano, Anthony C. Keech, J. Antonio G. López, Maria Laura Monsalvo, E. Magnus Ohman, Xinhui Ran, Sabina A. Murphy, Marc S. Sabatine, and Michelle L. O’Donoghue
Stay updated with Hemostasis today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits